RE:RE:RE:RE:RE:RE:Big pharma is set to keep signing bigger deals in 2024In January 2024 Bristol Myers Squibb (BMS) completed its acquisition of the Phase 3 small molecule company Mirati Therapeutics, Inc., which is now a wholly owned subsidiary of the company. The definitive merger agreement was reached in October 2023, with BMS acquiring Mirati for $58 per share in cash, for a total equity value of $4.8 billion.
Under the agreement, BMS obtains Mirati’s entire portfolio, including Krazati (adagrasib) in Phase 3 clinical trials for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC). Mirati’s oncology portfolio also includes promising early phase clinical assets such as MRTX1719, a potential first-in-class MTA-cooperative PRMT5 inhibitor currently in Phase I development, and a leading KRAS and KRAS enabling program with a pair of candidates in Phase I development.
Mirati’s KRAS and KRAS enabling program includes MRTX1133, which targets the KRASG12D mutation, and MRTX0902, a SOS1 inhibitor currently in the Phase 1 developmental stage as a combination therapy with other agents that target the MAPK/RAS pathway.
https://www.pharmexec.com/view/bristol-myers-squibb-completes-acquisition-of-mirati-to-bolster-oncology-pipeline